Literature DB >> 21229382

Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance.

Yousri M Hussein1, Amal F Gharib, Rasha L Etewa, Wael H ElSawy.   

Abstract

The HDL-associated paraoxonase (PON) activities play a role in decreasing oxidative stress, which is known to contribute to cancer development. The aim of this study was to examine the relation between the PON1 L55M and Q192R polymorphisms and breast cancer (BC) risk in Egyptian females and to analyze their relation to clinicopathological parameters of BC. Both polymorphisms were characterized in 100 BC Egyptian females and 100 healthy women who had no history of any malignancy by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, using DNA from peripheral blood in a case control study. With respect to PON1 L55M, the mutated allele (M) frequency was found in 70.5% in BC patients and in 53.5% in controls; the M allele was significantly associated with an increased risk of BC (adjusted odds ratio (OR(adj)) 2.07, 95% confidence interval (95% CI) 1.37-3.13; P = 0.011). The homozygous mutant genotype (MM) significantly increased the risk of BC (OR(adj) 2.07, 95% CI 1.17-3.64, P = 0.011). However, as regard PON1 Q192R, the R mutated allele frequency was found in 28.5% in BC patients and in 33% in controls, the women who were QR heterozygotes (OR(adj) 0.96, 95% CI 0.55-1.68) or RR homozygotes (OR(adj) 0.64, 95% CI 0.25-1.63), and R allele (OR(adj) 0.81, 95% CI 0.53-1.42) did not show any risk for BC. Both PON1 L55M and Q192R polymorphisms genotype frequencies were not related to patient's age (P = 0.94 and 0.72, respectively). M allele genotypes (LM/MM) carriers showed significant association only with nodal metastases (P = 0.02) but not with other clinicopathologic parameters. However, R allele genotype (QR/RR) carriers showed insignificant correlation with clinicopathological parameters. In conclusion, our results suggest that the M allele of L55M polymorphism could be a suitable marker for BC susceptibility and tumor prognosis in Egyptian women.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21229382     DOI: 10.1007/s11010-011-0718-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

1.  Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype.

Authors:  V H Brophy; G P Jarvik; R J Richter; L S Rozek; G D Schellenberg; C E Furlong
Journal:  Pharmacogenetics       Date:  2000-07

2.  Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort.

Authors:  Victoria L Stevens; Carmen Rodriguez; Alexandre L Pavluck; Michael J Thun; Eugenia E Calle
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

3.  VEGF 936C>T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls.

Authors:  Dongying Gu; Meilin Wang
Journal:  Breast Cancer Res Treat       Date:  2010-06-19       Impact factor: 4.872

4.  Lipid peroxidation and total antioxidant status in patients with breast cancer.

Authors:  Derya Erten Sener; Aymelek Gönenç; Melih Akinci; Meral Torun
Journal:  Cell Biochem Funct       Date:  2007 Jul-Aug       Impact factor: 3.685

5.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression.

Authors:  V H Brophy; R L Jampsa; J B Clendenning; L A McKinstry; G P Jarvik; C E Furlong
Journal:  Am J Hum Genet       Date:  2001-05-02       Impact factor: 11.025

6.  Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O-methyltransferase.

Authors:  Salama A Salama; Marwa Kamel; Mohamed Awad; Abdel-Hakim Ben Nasser; Ayman Al-Hendy; Shaleen Botting; Concepcion Arrastia
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

7.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis.

Authors:  D M Shih; L Gu; Y R Xia; M Navab; W F Li; S Hama; L W Castellani; C E Furlong; L G Costa; A M Fogelman; A J Lusis
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

8.  Carbonyl and oxidative stress in patients with breast cancer--is there a relation to the stage of the disease?

Authors:  P Tesarová; M Kalousová; B Trnková; J Soukupová; S Argalásová; O Mestek; L Petruzelka; T Zima
Journal:  Neoplasma       Date:  2007       Impact factor: 2.575

9.  Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease.

Authors:  Lisa Gallicchio; Meghan A McSorley; Craig J Newschaffer; Han-Yao Huang; Lucy W Thuita; Sandra C Hoffman; Kathy J Helzlsouer
Journal:  Cancer Detect Prev       Date:  2007-04-10

10.  Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer.

Authors:  Petra Tesarová; Marta Kalousová; Marie Jáchymová; Oto Mestek; Lubos Petruzelka; Tomás Zima
Journal:  Cancer Invest       Date:  2007-12       Impact factor: 2.176

View more
  16 in total

1.  Correlation between PON1 gene polymorphisms and breast cancer risk: a Meta-analysis.

Authors:  Yayuan Wen; Zemin Huang; Xiaohua Zhang; Bo Gao; Yujun He
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  Association between paraoxonase-1 gene Q192R and L55M polymorphisms in systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS) in a population from Cairo of Egypt.

Authors:  Alshaymaa Ahmed Ibrahim; Dalia El-Lebedy; Ingy Ashmawy; Maha Abdel Hady
Journal:  Clin Rheumatol       Date:  2017-02-09       Impact factor: 2.980

3.  PON1 status does not influence cholinesterase activity in Egyptian agricultural workers exposed to chlorpyrifos.

Authors:  Corie A Ellison; Alice L Crane; Matthew R Bonner; James B Knaak; Richard W Browne; Pamela J Lein; James R Olson
Journal:  Toxicol Appl Pharmacol       Date:  2012-09-10       Impact factor: 4.219

4.  Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 published studies.

Authors:  Dai-Hua Fang; Cong-Hai Fan; Qiang Ji; Bo-Xiang Qi; Juan Li; Lu Wang
Journal:  Mol Biol Rep       Date:  2012-02-10       Impact factor: 2.316

5.  Association of M55L and Q192R polymorphisms of paraoxonase 1 gene (PON1) with recurrent pregnancy loss risk: A case-control study.

Authors:  Mehdi Alizadeh; Mahboobeh Nasiri; Morteza Samadi; Nasrin Ghasemi; Ali Moradi
Journal:  Int J Reprod Biomed       Date:  2021-07-27

Review 6.  The Relationship between Cancer and Paraoxonase 1.

Authors:  Irma Martha Medina-Díaz; Néstor Ponce-Ruíz; Aurora Elizabeth Rojas-García; José Francisco Zambrano-Zargoza; Yael Y Bernal-Hernández; Cyndia Azucena González-Arias; Briscia S Barrón-Vivanco; José Francisco Herrera-Moreno
Journal:  Antioxidants (Basel)       Date:  2022-03-31

7.  Global DNA methylation and one-carbon metabolism gene polymorphisms and the risk of breast cancer in the Sister Study.

Authors:  Lisa A Deroo; Sophia C E Bolick; Zongli Xu; David M Umbach; David Shore; Clarice R Weinberg; Dale P Sandler; Jack A Taylor
Journal:  Carcinogenesis       Date:  2013-10-15       Impact factor: 4.944

8.  Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: a meta-analysis.

Authors:  Chibo Liu; Liu Liu
Journal:  Tumour Biol       Date:  2011-09-02

9.  Genetic polymorphisms in paraoxonase 1 and G protein-coupled receptor 77, and the risk of glucose-6-phosphate dehydrogenase deficiency in a Saudi population.

Authors:  Khalid K Alharbi
Journal:  Saudi Med J       Date:  2015-05       Impact factor: 1.484

10.  Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma.

Authors:  Hikmet Akkız; Sedef Kuran; Ersin Akgöllü; Oğuz Üsküdar; Aynur Bekar; Süleyman Bayram; Selçuk Yıldırım; Yakup Ülger; Berrin Yalınbaş Kaya; Mahmut Şansal; Ercan Çınar
Journal:  Meta Gene       Date:  2013-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.